Does the media refer more to ELOX or LPCN?

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Lipocine. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ATHE or LPCN?

Lipocine has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Lipocine $1.98M 9.20 -$9.63M -$1.79 N/A

Does the media favor ATHE or LPCN?

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 0.33 beat Lipocine's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TENX or LPCN?

In the previous week, Tenax Therapeutics had 7 more articles in the media than Lipocine. MarketBeat recorded 9 mentions for Tenax Therapeutics and 2 mentions for Lipocine. Tenax Therapeutics' average media sentiment score of 1.51 beat Lipocine's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LONA or LPCN more profitable?

Athira Pharma has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Lipocine -755.39% -64.75% -57.62%

Does the media prefer LPCN or SPRO?

In the previous week, Spero Therapeutics had 8 more articles in the media than Lipocine. MarketBeat recorded 10 mentions for Spero Therapeutics and 2 mentions for Lipocine. Spero Therapeutics' average media sentiment score of 1.16 beat Lipocine's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lipocine (LPCN) Competitors

$2.21 -0.01 (-0.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.22 +0.00 (+0.23%)

As of 09/18/2026 04:10 PM Eastern

Compare

LPCN vs. ELOX, ATHE, TENX, LONA, and SPRO

Should you buy Lipocine stock or one of its competitors? Lipocine's main competitors and comparable companies include Eloxx Pharmaceuticals (ELOX), Alterity Therapeutics (ATHE), Tenax Therapeutics (TENX), Athira Pharma (LONA), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lipocine compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Lipocine. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eloxx Pharmaceuticals has higher revenue and earnings than Lipocine. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	11.08	-$5.99M	-$1.54	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Lipocine	-755.39%	-64.75%	-57.62%

Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its stock price is 186,326% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, suggesting a potential upside of 119.68%. Lipocine has a consensus price target of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's higher possible upside, analysts plainly believe Lipocine is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Eloxx Pharmaceuticals beats Lipocine on 12 of the 16 factors compared between the two stocks.

How does Lipocine compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Lipocine has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 0.33 beat Lipocine's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alterity Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Alterity Therapeutics' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Lipocine	-755.39%	-64.75%	-57.62%

Alterity Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 155.75%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 578.73%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

Alterity Therapeutics beats Lipocine on 7 of the 12 factors compared between the two stocks.

How does Lipocine compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Tenax Therapeutics had 7 more articles in the media than Lipocine. MarketBeat recorded 9 mentions for Tenax Therapeutics and 2 mentions for Lipocine. Tenax Therapeutics' average media sentiment score of 1.51 beat Lipocine's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Lipocine has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A

Tenax Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 636.84%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 578.73%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tenax Therapeutics is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tenax Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Tenax Therapeutics' return on equity of -61.54% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Lipocine	-755.39%	-64.75%	-57.62%

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tenax Therapeutics beats Lipocine on 12 of the 16 factors compared between the two stocks.

How does Lipocine compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 4.7% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lipocine has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A

Athira Pharma presently has a consensus target price of $17.33, suggesting a potential upside of 155.28%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, Lipocine had 2 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Lipocine	Neutral

Athira Pharma has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Lipocine	-755.39%	-64.75%	-57.62%

Summary

Lipocine beats Athira Pharma on 8 of the 14 factors compared between the two stocks.

How does Lipocine compare to Spero Therapeutics?

Lipocine (NASDAQ:LPCN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Spero Therapeutics has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A
Spero Therapeutics	$66.80M	0.99	$8.57M	$0.11	10.27

In the previous week, Spero Therapeutics had 8 more articles in the media than Lipocine. MarketBeat recorded 10 mentions for Spero Therapeutics and 2 mentions for Lipocine. Spero Therapeutics' average media sentiment score of 1.16 beat Lipocine's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.1% of Lipocine shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lipocine has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Lipocine's net margin of -755.39%. Spero Therapeutics' return on equity of 16.17% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Spero Therapeutics	24.90%	16.17%	12.57%

Lipocine presently has a consensus price target of $15.00, suggesting a potential upside of 578.73%. Spero Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 430.97%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Spero Therapeutics beats Lipocine on 13 of the 16 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.22M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-1.24	797.25	275.49	25.40
Price / Sales	9.20	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.85	10.53	10.46	6.33
Net Income	-$9.63M	$2.82B	$3.49B	$358.33M
7 Day Performance	-2.64%	1.69%	0.59%	1.12%
1 Month Performance	5.74%	0.24%	-1.74%	-2.39%
1 Year Performance	-23.26%	3.95%	18.13%	5.35%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	1.6429 of 5 stars	$2.21 -0.5%	$15.00 +578.7%	-23.3%	$18.22M	$1.98M	N/A	14	Gap Up
ELOX Eloxx Pharmaceuticals	2.4476 of 5 stars	$17.55 -0.5%	$41.50 +136.5%	N/A	$70.90M	$6.36M	N/A	7	News Coverage Analyst Forecast Gap Up
ATHE Alterity Therapeutics	3.2581 of 5 stars	$3.85 +0.0%	$10.00 +159.7%	-12.7%	$69.82M	N/A	N/A	11	News Coverage Analyst Forecast
TENX Tenax Therapeutics	4.0437 of 5 stars	$1.86 +2.2%	$14.00 +652.7%	-70.4%	$69.60M	N/A	N/A	16	Positive News Insider Trade Short Interest Increase Gap Up
LONA Athira Pharma	2.3521 of 5 stars	$6.95 +2.4%	$17.33 +149.4%	N/A	$65.26M	N/A	N/A	19	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. ELOX, ATHE, TENX, LONA, and SPRO

How does Lipocine compare to Eloxx Pharmaceuticals?

Summary

How does Lipocine compare to Alterity Therapeutics?

Summary

How does Lipocine compare to Tenax Therapeutics?

Summary

How does Lipocine compare to Athira Pharma?

Summary

How does Lipocine compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. ELOX, ATHE, TENX, LONA, and SPRO

How does Lipocine compare to Eloxx Pharmaceuticals?

Do institutionals and insiders have more ownership in ELOX or LPCN?

Does the media refer more to ELOX or LPCN?

Which has stronger earnings and valuation, ELOX or LPCN?

Is ELOX or LPCN more profitable?

Which has more volatility and risk, ELOX or LPCN?

Do analysts recommend ELOX or LPCN?

Summary

How does Lipocine compare to Alterity Therapeutics?

Which has stronger valuation & earnings, ATHE or LPCN?

Does the media favor ATHE or LPCN?

Do institutionals & insiders believe in ATHE or LPCN?

Is ATHE or LPCN more profitable?

Do analysts rate ATHE or LPCN?

Which has more risk and volatility, ATHE or LPCN?

Summary

How does Lipocine compare to Tenax Therapeutics?

Does the media favor TENX or LPCN?

Which has more risk and volatility, TENX or LPCN?

Which has stronger valuation and earnings, TENX or LPCN?

Do analysts prefer TENX or LPCN?

Is TENX or LPCN more profitable?

Do insiders and institutionals believe in TENX or LPCN?

Summary

How does Lipocine compare to Athira Pharma?

Do institutionals & insiders believe in LONA or LPCN?

Which has better valuation & earnings, LONA or LPCN?

Do analysts rate LONA or LPCN?

Which has more volatility and risk, LONA or LPCN?

Does the media favor LONA or LPCN?

Is LONA or LPCN more profitable?

Summary

How does Lipocine compare to Spero Therapeutics?

Which has higher valuation & earnings, LPCN or SPRO?

Does the media prefer LPCN or SPRO?

Do institutionals and insiders hold more shares of LPCN or SPRO?

Which has more risk and volatility, LPCN or SPRO?

Is LPCN or SPRO more profitable?

Do analysts prefer LPCN or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools